The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Open accessAbstract
Purpose: Systemic exposure to mercaptopurine (MP) is critical for durable remissions in children with acute lymphoblastic leukemia (ALL). Nonadherence to oral MP could increase relapse risk and also contribute to inferior outcome in Hispanics. This study identified determinants of adherence and described impact of adherence on relapse, both overall and by ethnicity. Patients and Methods: A total of 327 children with ALL (169 Hispanic; 158 non-Hispanic white) participated. Medication event-monitoring system caps recorded date and time of MP bottle openings. Adherence rate, calculated monthly, was defined as ratio of days of MP bottle opening to days when MP was prescribed. Results: After 53,394 person-days of monitoring, adherence declined from 94.7% (month 1) to 90.2% (month 6; P < .001). Mean adherence over 6 months was significantly lower among Hispanics (88.4% v 94.8%; P < .001), patients age ≥ 12 years (85.8% v 93.1%; P < .001), and patients from single-mother households (80.6% v 93.1%; P = .001). A progressive increase in relapse was observed with decreasing adherence (reference: adherence ≥ 95%; 94.9% to 90%: hazard ratio [HR], 4.1; 95% CI,1.2 to 13.5; P = .02; 89.9% to 85%: HR, 4.0; 95% CI, 1.0 to 15.5; P = .04; < 85%: HR. 5.7; 95% CI, 1.9 to 16.8; P = .002). Cumulative incidence of relapse (± standard deviation) was higher among Hispanics (16.5% ± 4.0% v 6.3% ± 2.2%; P = .02). Association between Hispanic ethnicity and relapse (HR, 2.6; 95% CI, 1.1 to 6.1; P = .02) became nonsignificant (HR, 1.8; 95% CI, 0.6 to 5.2; P = .26) after adjusting for adherence and socioeconomic status. At adherence rates ≥ 90%, Hispanics continued to demonstrate higher relapse, whereas at rates < 90%, relapse risk was comparable to that of non-Hispanic whites. Conclusion: Lower adherence to oral MP increases relapse risk. Ethnic difference in relapse risk differs by level of adherence—an observation currently under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Unequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
Capps, L. (2003) · JAMA · doi:10.1001/jama.290.18.2487-b · Cited by 4,526
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Self-citationTreatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
How often is medication taken as prescribed? A novel assessment technique
Cramer, J. A. (1989) · JAMA · doi:10.1001/jama.261.22.3273 · Cited by 1,021
Smith, M., Arthur, D., Camitta, B., Carroll, A. J., Crist, W., Gaynon, P., Gelber, R., Heerema, N., Korn, E. L., Link, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.18 · Cited by 901
Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., & Evans, W. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2001 · Cited by 733
Self-citationCytogenetics in acute leukemia
Mrózek, K., Heerema, N. A., & Bloomfield, C. D. (2004) · Blood Reviews · doi:10.1016/s0268-960x(03)00040-7 · Cited by 659
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2008) · Cancer · doi:10.1002/cncr.23169 · Cited by 643
Harvey, R. C., Mullighan, C. G., Chen, I.-M., Wharton, W., Mikhail, F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245944 · Cited by 574
Self-citationSocial desirability and response to perceived situational demands.
Marlow, D., & Crowne, D. P. (1961) · Journal of Consulting Psychology · doi:10.1037/h0041627 · Cited by 456
A review of adjusted estimators of attributable risk
Benichou, J. (2001) · Statistical Methods in Medical Research · doi:10.1177/096228020101000303 · Cited by 440
Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia
Relling, M. V., Hancock, M. L., Boyett, J. M., Pui, C.-H., & Evans, W. E. (1999) · Blood · doi:10.1182/blood.v93.9.2817 · Cited by 395
Self-citationAncestry and pharmacogenomics of relapse in acute lymphoblastic leukemia
Yang, J. J., Cheng, C., Devidas, M., Cao, X., Fan, Y., Campana, D., Yang, W., Neale, G., Cox, N. J., Scheet, P., et al. (2011) · Nature Genetics · doi:10.1038/ng.763 · Cited by 274
Self-citationRacial and ethnic differences in survival of children with acute lymphoblastic leukemia
Bhatia, S., Sather, H. N., Heerema, N. A., Trigg, M. E., Gaynon, P. S., & Robison, L. L. (2002) · Blood · doi:10.1182/blood-2002-02-0395 · Cited by 270
Self-citationSurvival Variability by Race and Ethnicity in Childhood Acute Lymphoblastic Leukemia
Kadan-Lottick, N. S. (2003) · JAMA · doi:10.1001/jama.290.15.2008 · Cited by 244
Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard, L., & Lilleyman, J. S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1816 · Cited by 244
The Electronic Medication Event Monitor: Lessons for Pharmacotherapy
Urquhart, J. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00001 · Cited by 206
Barriers to HAART Adherence Among Human Immunodeficiency Virus–Infected Adolescents
Murphy, D. A. (2003) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.157.3.249 · Cited by 203
Pollock, B. H., DeBaun, M. R., Camitta, B. M., Shuster, J. J., Ravindranath, Y., Pullen, D. J., Land, V. J., Mahoney, D. H., Lauer, S. J., & Murphy, S. B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.813 · Cited by 178
Compliance of pediatric and adolescent cancer patients
Tebbi, C. K., Cummings, K. M., Zevon, M. A., Smith, L., Richards, M., & Mallon, J. (1986) · Cancer · doi:10.1002/1097-0142(19860901)58:5<1179::aid-cncr2820580534>3.0.co;2-e · Cited by 178
Yang, Y., Thumula, V., Pace, P. F., Banahan, B. F., Wilkin, N. E., & Lobb, W. B. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.002 · Cited by 155
Systemic Exposure to Mercaptopurine as a Prognostic Factor in Acute Lymphocytic Leukemia in Children
Koren, G., Ferrazzini, G., Sulh, H., Langevin, A. M., Kapelushnik, J., Klein, J., Giesbrecht, E., Soldin, S. J., & Greenberg, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230104 · Cited by 138
Trinacty, C. M., Adams, A. S., Soumerai, S. B., Zhang, F., Meigs, J. B., Piette, J. D., & Ross‐Degnan, D. (2009) · BMC Health Services Research · doi:10.1186/1472-6963-9-24 · Cited by 93
Lennard, L., Welch, J. C., & Lilleyman, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.450 · Cited by 76
Lau, R. C. W., Matsui, D. M., Greenberg, M., & Koren, G. (1998) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199802)30:2<85::aid-mpo3>3.0.co;2-w · Cited by 64
Understanding Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: A Review
Pritchard, M. T., Butow, P. N., Stevens, M. M., & Duley, J. A. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000243666.79303.45 · Cited by 53
Biology and virology of the human malignant lymphomas.1st Milford D. Schulz lecture
Kaplan, H. S., Goodenow, R. S., Gartner, S., & Bieber, M. M. (1979) · Cancer · doi:10.1002/1097-0142(197901)43:1<169::aid-cncr2820430125>3.0.co;2-f · Cited by 41
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui, C.-H., Mullighan, C. G., Evans, W. E., & Relling, M. V. (2012) · Blood · doi:10.1182/blood-2012-05-378943 · Cited by 500
Self-citationYang, J. J., Landier, W., Yang, W., Liu, C., Hageman, L., Cheng, C., Pei, D., Chen, Y., Crews, K. R., Kornegay, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4671 · Cited by 445
Self-citationA 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.007 · Cited by 368
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J. M., Tallman, M. S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3078 · Cited by 350
Metadata
- Authors
- Bhatia, S., Landier, W., Shangguan, M., Hageman, L., Schaible, A. N., Carter, A. R., Hanby, C. L., Leisenring, W., Yasui, Y., Kornegay, N. M., Mascarenhas, L., Ritchey, A. K., Casillas, J. N., Dickens, D. S., Meza, J., Carroll, W. L., Relling, M. V., & Wong, F. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-06-10
- Volume
- 30
- Issue
- 17
- Pages
- 2094-2101
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103564256
- Cited by
- 340
- References
- 33
- FWCI
- 21.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.